St.-Josef-Stift
- Address
- lock Available on a paid plan
Immune System Diseases and Immune System Processes
At St.-Josef-Stift in Sendenhorst, research in this area focuses on autoimmune and inflammatory conditions, with studies designed to better understand treatment response, safety, and how therapies behave in the body. The trials are centered on improving care for patients with juvenile idiopathic arthritis, rheumatoid arthritis, and related immune-mediated diseases.
- Evaluating new and existing therapies for juvenile idiopathic arthritis subtypes in children and adolescents
- Studying treatment safety, tolerability, and body-handling of medicines used for pediatric inflammatory arthritis
- Assessing approaches aimed at reducing disease activity in systemic and polyarticular forms of arthritis
The site contributes to clinical research that supports better long-term management of immune-mediated musculoskeletal disorders, with a strong emphasis on treatment effectiveness and patient safety.
Musculoskeletal Diseases
Clinical trials at this hospital-based research site also address musculoskeletal inflammatory diseases, especially conditions that affect joints, movement, and overall function. The research is aimed at identifying therapies that may improve symptom control and help reduce relapses in both pediatric and adult patients.
- Testing therapies for rheumatoid arthritis and related inflammatory joint disease
- Exploring options for giant cell arteritis to delay clinical relapse and maintain remission
- Investigating treatment strategies for juvenile idiopathic arthritis and its more active subtypes
These studies reflect a broader effort to improve outcomes in rheumatology by evaluating whether new treatments can offer better disease control and a favorable safety profile.
Autoimmune Rheumatology Research
The clinical trial portfolio includes studies of autoimmune rheumatic diseases across different age groups, from children with inflammatory arthritis to adults living with chronic immune-driven muscle disease. Research here is focused on finding therapies that may offer meaningful benefits while remaining well tolerated over time.
- Assessing long-term safety and tolerability in idiopathic inflammatory myopathy
- Measuring treatment effectiveness in active juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis
- Comparing investigational treatment options for giant cell arteritis and rheumatoid arthritis
Overall, the research at St.-Josef-Stift highlights a strong commitment to advancing care for immune-related inflammatory disorders through studies that examine safety, efficacy, and clinical benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St.-Josef-Stift
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized open-label study to assess the efficacy, safety, and pharmacokinetics of upadacitinib with a tocilizumab reference arm in subjects from 1 year to less than 18 years old with active systemic juvenile idiopathic arthritis. | AbbVie Deutschland GmbH & Co. KG | Phase III | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tocilizumab | 2 | Unknown | 2024-03-19 | 2026-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.